Clearside Biomedical - Chapter 11 Plan Terms

Clearside Biomedical's plan-sponsor reorganization centers on a Steel Partners-led recapitalization, whereby Steel purchases newly issued Class B Common Stock for up to $2.2 million to secure roughly 30% of the economics and 80% of the voting power alongside a $3 million SOFR+700 senior secured revolving credit facility, while the debtor monetizes its royalty and pipeline assets through a $6 million Excess Royalties sale to HCR and a $4 million Remaining Assets sale to Health Ocean, leaving existing shareholders with approximately 70% of the reorganized equity (20% of the vote) as Class A Common Stock plus a Class A Cash Distribution consisting of whatever cash remains in the $1 million claims reserve after payment of all bankruptcy expenses, all structured to preserve the company's NOLs and tax attributes.

Plan Terms

Overview

New Common Equity Purchase

Credit Facility

Sale Transactions

Royalty Agreement

Asset Retention

Treatment of Existing Equity

Reverse Stock Split

Corporate Governance

Post-Emergence Structure

Preservation of Tax Attributes

Conditions to Steel Partners’ Obligations

Termination Events

Conditions to the Effective Date

HCR Settlement

Arctic Vision Settlement

Officer Settlement

Ad Hoc Group Settlement

Releases

Exculpation

Voting and Confirmation